Relationship between BIM gene polymorphism and therapeutic efficacy in platinum drugs treated advanced non-small cell lung cancer

doi:10.3877/cma.j.issn.1674-6902.2017.06.014

Abstract

Abstract:

Objective

To explore the relationship between BIM gene polymorphism and therapeutic efficacy in the advanced non-small cell lung cancer (NSCLC) with platinum drugs.

Methods

It was collected that 100 patients who were diagnosed with advanced NSCLC and received therapy with platinum drugs in oncology department of Chongqing Traditional Chinese Medicine Hospital from July 2012 to July 2015. The peripheral blood of patients was collected and genotype of BIM gene polymorphism was detected by polymerase chain reaction (PCR). Statistical analysis was performed by SPSS version 13.0.

Results

On the objective response rate(ORR), BIM gene with no polymorphism type was significantly better trend than polymorphism types in ORR(48.8% vs. 11.1%, χ²=8.598, P=0.003). The BIM gene polymorphism was the independent prognostic factors for progressin-free survival (PFS) by univariate Cox analysis. The median PFS in BIM gene with no polymorphism type were significantly longer than with polymorphism type(14.0 months vs. 10.0 months, P=0.001). However, BIM gene polymorphism did not have significant influence on adverse drug reaction (χ²=1.62, P>0.1).

Conclusions

The BIM gene polymorphism is the independent prognostic factor for PFS in patients of NSCLC, and detection of BIM gene polymorphism is important for prognostic evaluation of therapeutic efficacy in the advanced NSCLC with platinum drugs.

Key words: Non-small cell lung cancer, BIM gene polymorphism, Platinum drugs

Jianghong Zhu, Yong Liu, Jun Cheng, Lingzhan Meng, Liang Ai, Na Liu, Wenjuan Zou. Relationship between BIM gene polymorphism and therapeutic efficacy in platinum drugs treated advanced non-small cell lung cancer[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2017, 10(06): 698-703.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2017.06.014

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2017/V10/I06/698

Figures/Tables 4

References 34

1	钱桂生. 肺癌不同病理类型发病率的变化情况及原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1):1-6.
2	Santarpia M, Liguori A, Karachaliou N, et al. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy[J]. Lung Cancer (Auckl), 2017, 8:109-125.
3	Wu H, Medeiros LJ, Young KH. Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances[J]. Blood Rev, 2017, doi: 10.1016/j.blre.2017.08.004.
4	Karachaliou N, Rosell R, Molina MA, et al. Predicting resistance by selection of signaling pathways[J]. Transl Lung Cancer Res, 2014, 3(2):107-115.
5	Katagiri S, Umezu T, Ohyashiki JH, et al. The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients[J]. Br J Haematol, 2013, 160(2):269-271.
6	Ng KP, Hillmer AM, Chuah CT, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer[J]. Nat Med, 2012, 18(4):521-528.
7	Richter-Larrea JA, Robles EF, Fresquet V, et al. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma[J]. Blood, 2010，116(14):2531-2542.
8	Wang J, Zhou JY, Wu GS. Bim protein degradation contributes to cisplatin resistance[J]. J Biol Chem, 2011, 286(25):22384-22392.
9	Zhong J, Li ZX, Zhao J, et al. Analysis of BIM (BCL-2 like 11 gene) deletion polymorphism in Chinese Non-small cell lung cancer patients[J]. Thoracic Cancer, 2014, 5(6):509-516.
10	Eisenhauer EA, Thersasse P, Bogaerts J, et al. New respongse evaluation criteria in solid tumors: revised RECIST guideline [J]. Eur J Cancer, 2009, 45(2):228-247.
11	Trotti A, Bentzen SM. The need for adverse effects reporting standards in oncology clinical trials[J]. J Clin Oncol, 2004, 22(1):19-22.
12	吕洋，苗立云. 非小细胞肺癌分子靶向药物耐药机制的研究进展[J/CD]. 中华肺部疾病杂志(电子版), 2015, 8(1):82-84.
13	Bouillet P, Zhang LC, Huang DC, et al. Gene structure alternative splicing, and chromosomal localization of pro-apoptotic Bcl-2 relative Bim[J]. Mamm Genome, 2001, 12(2):163-168.
14	Hsu SY, Lin P, Hsueh AJ. BOD(Bcl-2-related ovarian death gene) is an ovarian BH3 domain-containing proapoptotic Bcl-2 protein capable of dimerization with diverse antiapoptotic Bcl-2 members[J]. Mol Endocrinol, 1998, 12(9):1432-1440.
15	Qian K, Zhang Y, Zhi X. Retrospective Study of Efficacy in BIM Gene Polymorphism on First-line EGFR-TKIs Treatment for Advanced Lung Adenocarcinoma[J]. Zhongguo Fei Ai Za Zhi, 2017, 20(8):543-548.
16	Cheng F, Pan Y, Lu YM, et al. RNA-Binding Protein Dnd1 Promotes Breast Cancer Apoptosis by Stabilizing the Bim mRNA in a miR-221 Binding Site[J]. Biomed Res Int, 2017, 2017:e9596152.
17	Kim KO, Hsu AC, Lee HG, et al. Proteomic identification of 14-3-3∈ as a linker protein between pERK1/2 inhibition and BIM upregulation in human osteosarcoma cells[J]. J Orthop Res, 2014, 32(6):848-854.
18	Gambichler T, Rooms I, Scholl L, et al. BH3-only protein Bim predicts advanced stage of cutaneous melanoma[J]. J Eur Acad Dermatol Venereol, 2016, 30(11):1926-1929.
19	Faber AC, Ebi H, Costa C, et al. Apoptotic in targeted therapy responses: the role of BIM[J]. Adv Pharmacol, 2012, 65:519-542.
20	Zou Q, Zhan P, Lv T, et al. The relationship between BIM deletion polymorphism and clinical significance of epidermal growth factor receptor-mutated non-small cell lung cancer patients with epidermal growth factor receptor-tyrosine kinase inhibitor therapy: a meta-analysis[J]. Transl Lung Cancer Res, 2015, 4(6):792-796.
21	Lee HY, Kim IK, Lee HI, et al. The apoptotic effect of simvastatin via the upregulation of BIM in nonsmall cell lung cancer cells[J]. Exp Lung Res, 2016, 42(1):14-23.
22	Ying HQ, Chen J, He BS, et al. The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy[J]. Sci Rep, 2015, 5:doi: 10.1038/srep11348.
23	Kaufmann T, Jost PJ, Pellegrini M, et al. Fatal hepatitis mediated by tumor necrosis factor TNFalpha requires caspase-8 and involves the BH3-only proteins Bid and Bim[J]. Immunity, 2009, 30(1):56-66.
24	Willis SN, Adams JM. Life in the balance: how BH3-only proteins induce apoptosis[J]. Curr Opin Cell Biol, 2005, 17(6):617-625.
25	Costa DB, Halmos B, Kumar A, et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations[J]. PLoS Med, 2007, 4(10):1669-1679.
26	Gong Y, Somwar R, Politi K, et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR dependent lung adenocarcinomas[J]. PLoS Med, 2007, 4:e294.
27	Lee JH, Lin YL, Hsu WH, et al. BCL-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cance[J]J Thorac Oncol, 2014, 9(9):1385-1392.
28	Akiyama T, Dass CR, Choong PF. Bim-targeted cancer therapy：a link between drug action and unde rlying molecular changes[J]. Mol Cancer Ther, 2009, 8(12):3173-3180.
29	Wu YL, Saijo N, Thongprasert S, et al. Efficacy according to blind independent central review: Post-hoc analyses from the phase Ⅲ，randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC[J]. Lung Cancer, 2017, 104:119-125.
30	Wu YL, Fukuoka M, Mok TS, et al. Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study[J]. Lung Cancer, 2013, 81(2):280-287.
31	Xia JJ, Xiong LW, Chu TQ, et al. Association between BIM deletion polymorphism and the risk of non-small cell lung cancer in Chinese[J]. Int J Clin Exp Pathol, 2016, 9(5):5647-5655.
32	Sun S, Yu H, Wang H, et al. Exploratory cohort study and meta－analysis of BIM deletion polymorphism in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors[J]. Onco Targets Ther, 2017, 10:1955-1967.
33	Ma JY, Yan HJ, Gu W. Association between BIM deletion polymorphism and clinical outcome of EGFR-mutated NSCLC patient with EGFR-TKI therapy: A meta-analysis[J]. J Cancer Res Ther, 2015, 11(2):397-402.
34	Lee JH, Lin YL, Hsu WH, et al. Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer[J]. J Thorac Oncol, 2014, 9(9):1385-1392.

临床资料	B	SE	Wald	Sig.	Exp(B)(95%CI)
年龄	0.009	0.014	0.444	0.505	0.991
性别	0.345	0.284	1.473	0.225	1.412
TNM分期	0.513	0.287	3.194	0.074	1.670
病理类型	0.437	0.251	3.038	0.081	1.548
BIM多态性	1.206	0.407	8.798	0.003	3.339

临床资料	B	SE	Wald	Sig.	Exp(B)(95%CI)
年龄	0.009	0.014	0.444	0.505	0.991
性别	0.345	0.284	1.473	0.225	1.412
TNM分期	0.513	0.287	3.194	0.074	1.670
病理类型	0.437	0.251	3.038	0.081	1.548
BIM多态性	1.206	0.407	8.798	0.003	3.339

组　别	例数	有不良反应	无不良反应	χ²值	P值
野生型	82	58(60.68)	24(21.32)	1.67	0.196
缺失型及混合型	18	16(13.32)	2(4.94)	?	?
合　计	?	74	26	?	?

组　别	例数	有不良反应	无不良反应	χ²值	P值
野生型	82	58(60.68)	24(21.32)	1.67	0.196
缺失型及混合型	18	16(13.32)	2(4.94)	?	?
合　计	?	74	26	?	?

[1]	Song Liu, Jinzhao Zhang, Yanyun Jia. Relationship between reduced response to pabolizumab in treatment of advanced non-small cell lung cancer and antibiotic preconditioning [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 553-557.
[2]	Xiaoyu Han, Keyu Li, Zhifei Zhao, Jianping Gao. Prognostic significance of SNHG17 overexpression for non-small cell lung cancer resection [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 543-547.
[3]	Guiping Zhang, Yonglin Qiu, Qiting Zhan, Ledong Sun. Prognostic significance of serum Ape1/Ref-1 for the radioactive lung injury in patients with advanced non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 519-523.
[4]	Mengmeng Zhao, Jie Huang, Ronghuan Yu, Baoqing Wang. Overexpression of the small GTPase Rab32 inhibits the invasive growth of non-small cell lung cancer cells [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 512-518.
[5]	Duo Li, Zhaozhao Hao, Yanwei Chen, Yandong Nan. Correlation analysis of serum PTX3 expression and bone metastasis in non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 558-562.
[6]	Lili Bai, Yu Jiang, Liangliang Huang, Ying BAI, Min Zhang. Application of occupational therapy in postoperative rehabilitation of patients with non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(03): 411-415.
[7]	Haiyan Zhao, Haitao Jin, ying Kong, Ruiyuan He. Prognostic significance of plasma NGS-ctDNA in patients with advanced NSCLC treated with EGFR-TKIs [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(03): 385-391.
[8]	Jing Yang, Jian Fu, Yanxia Kang. Significance of plasma ctDNA T790M mutation and total metabolic tumor volume in the prognostic significance of TKIs treatment in patients with advanced EGFR mutant NSCLC [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(03): 379-384.
[9]	Zhen Wang, Lu Huang, Lianqun Lang, Lu Yue. Prognostic significance of platelet and albumin/fibrinogen ratio in second-line therapy of bevacizumab for advanced non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(01): 35-40.
[10]	Jing Li, Guoyuan Ling, Shan Jiang, Xiaoju Chen, Xiaoyun Guo. Efficacy of pemetrexed delivery via ommaya capsule implantation versus lumbar puncture in treatment of leptomeningeal metastasis of non-small cell lung cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(02): 128-132.
[11]	Yang Li, Kunliang Guo, Bicheng Zhan, Quanquan Hu, Yuzhen Dai. Clinicopathological and molecular genetic characteristics and programmed cell death 1 ligand 1 expression in SMARCA4-deficient non-small cell lung cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(12): 1309-1314.
[12]	Meisi Liang, Huimin Lan, Ting Yu, Shengqiao Li. The study of plumbagin on suppressing the proliferation of non-small cell lung cancer [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2024, 12(02): 120-125.
[13]	Zijian Li, Rui Wang, Yunpeng Zhong, Dixuan Zhang, Yunjuan Liang, Chao Yang, Jianxing He, Shuben Li. Clinical application of lung autotransplantation in thoracic malignancies [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2024, 11(03): 193-200.
[14]	Xunfu Zhang, Jinshan Ma, Yunlong Jiang, Tuoleheng Jianati, Changjian Hou, Silajiding Sawuti. Expression and clinicopathological significance of GATA3 protein in non-small cell lung cancer tissues [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2024, 11(03): 175-179.
[15]	Kuan Xu, Heng Zhao, Bo Ye. Interpretation of the surgical section of the 2024 first edition of the National Comprehensive Cancer Network (NCCN) guidelines for non-small cell lung cancer [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2024, 11(02): 79-84.

Please choose a citation manager

Content to export